EMR

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✗

Return

+1.74%

Status

scored

Trim 25-30% of EMR exposure on any retest of the $160-164 distribution zone that fails to close above $164.31 on volume, retaining 70-75% as core with structural defense at the 200 SMA (~$144). Hard exit trigger is a weekly close below $144, with re-engagement targets at $153-155 pullback (RSI cooling toward 50-55, MACD positive) or confirmed close above $165.41 on volume greater than 4M. The 21.9x forward P/E prices execution perfection into a binary Q4 FY26 catalyst (~4 weeks away), with 1:1.3 risk/reward favoring trim scenarios.

Outcome

✓

Return

-0.10%

Status

scored

Trim 20-25% of EMR in two tranches into the $163-165 distribution zone while retaining 75-80% as core, with the trim ceiling explicitly upgraded from the standard 10-15% floor per the 10/06 binding reflection when the stretched+negative-R/R+binary-catalyst template is in force. Set the protective stop on the residual core at $168 (1.2 ATR above entry zone) rather than the trader's $165.79, with hard invalidation at daily close below $154.79 on volume confirmation, and pre-commit re-engagement triggers at $153-155 pullback or confirmed breakout above $164.20 on volume >4M through Q4 FY26 earnings.

Outcome

✓

Return

-1.35%

Status

scored

Emerson Electric receives an Underweight rating with a recommendation to trim 10-15% of the long position at current levels ($164), as the risk/reward is negative at upper Bollinger Band resistance with a 35x P/E, no margin of safety, and a binary November catalyst 6-9 weeks away. The core position (85-90%) is defended by structural anchors including the rising 200 SMA at $143.82, Aristocrat dividend status, sub-2x leverage, and $3.7B TTM FCF coverage. A tighter protective stop at $150 replaces the prior $148 level, and re-engagement is planned at $153-155 pullback zones or confirmed breakout above $164.20 on volume.

Outcome

✓

Return

-0.57%

Status

scored

Trim 10-15% of EMR into $160-162 strength to monetize the +5.7% gain from $153 entry, while maintaining 85-90% core given structural defenses (200 SMA at $143.82, sub-2x net debt/EBITDA, $3.7B TTM FCF). Hard stop at $148 with re-engagement triggers at $153-155 pullback or confirmed close above $162.13 on volume >4M.

Outcome

✓

Return

+0.45%

Status

scored

Maintain EMR at benchmark weight (2-3%) as the stock consolidates healthily without confirmed breakout. Do not add above $156 given two rejections at $159-164 with lower highs ($164.29→$159.39) signaling overhead supply, plus November Q4 FY26 earnings binary risk at 22× forward earnings with asymmetric downside. Add only on pullback to $153.50-$155.60 (10 EMA/50 SMA confluence) or confirmed daily close above $164.29 on volume >4M shares; trim partial profits into $160-$162 strength rather than waiting for earnings.

Outcome

✗

Return

+1.92%

Status

scored

Maintain EMR at benchmark weight (2-3% target) without adding at current $155.10 levels due to valuation stretch (33.9x trailing P/E, 1.79 PEG) and unresolved macro headwinds (10Y at 2002 highs, 97% probability of zero 2026 Fed cuts). Hard stop at $148.30, with add triggers at confirmed $159.39 breakout (volume >2.5M, MACD histogram >+1.0, RSI >60) or bullish reversal at 200 SMA ($143.58) with yields below 4.50%, and full exit on weekly close below $141.50.

Outcome

✗

Return

+2.24%

Status

scored

Underweight rating on EMR with a 10-15% position trim at $157, retaining 85-90% as core. The decision is calibrated to prior reflection guidance that explicitly calls for a modest trim when price rides upper Bollinger with approximately 1:1 risk/reward and a binary catalyst 6-9 weeks away. Hard stop set at $142-143 (200 SMA/lower Bollinger confluence), with add triggers at the $144-148 pullback zone or confirmed close above $160 on volume exceeding 2.5M.

Outcome

✓

Return

-1.36%

Status

scored

Trim EMR 10-15% ahead of the early-to-mid November Q4 FY26 earnings catalyst, retaining 85-90% as core position. The rating reflects a 1:1 risk/reward setup with price pinned to the upper Bollinger Band at $157.91 and weak volume confirmation, balanced against structural defenses including the 200 SMA at $143 and 24-year dividend Aristocrat status.

Outcome

✓

Return

-1.35%

Status

scored

Maintain EMR at Hold with a neutral-to-slightly-below-benchmark weight (target 2-3%) as the entry at ~$158 is technically extended above the upper Bollinger Band with negative near-term risk/reward (8.4% downside to $142 stop vs. 3.7-7.5% upside to $160-170 resistance). Add zones are established at $145-148 (Buy Zone 1, near 200 SMA) and $138-140 (Buy Zone 2, deeper structural retest), with hard stop at $142 and full exit on weekly close below $141.50. The Q4 FY26 earnings print in early November 2026 is the primary catalyst, along with November FOMC clarity on macro conditions.

Outcome

✗

Return

+0.73%

Status

scored

Trim 15-20% of EMR position on confirmed push above $160 with volume >2.5M and follow-through close, retaining 80-85% as core—this Underweight rating accepts directional caution given price extension above upper Bollinger band on weak volume and 50-60% historical EPS disappointment probability, but applies a smaller trim than the Research Manager's 25-40% based on binding 9/21 and 9/24 reflections documenting that moderating setups should drop trim ceilings toward Hold or 10-15%. Tighter stop at $150-151 (just below 50 SMA at $152.60 and Bollinger midline at $151.18) with hard exit on weekly close below $145.83.

Outcome

✓

Return

+1.34%

Status

scored

Maintain EMR at neutral weight (~2-3% target) at ~$156, with price trapped between the 50 SMA ($151.84) and upper Bollinger Band ($158.59), avoiding both addition and trimming into pre-FOMC volatility through a three-trigger conditional framework for action over a 6-9 week horizon.

Outcome

✓

Return

+1.00%

Status

scored

Maintain neutral weight at 2-3% target with no addition at $154.59 due to unconfirmed breakout and mathematically incorrect asymmetric risk/reward thesis (entry $154.59 to stop $143 = $11.59 risk vs first target $164.80 = $10.21 reward, yielding negative R/R). Trim 25-33% only on confirmed move to $158-164 resistance zone with volume, hedge residual with $150 strike March 2026 puts at ~3% of position, and re-engage aggressively only on confirmed close above $158.39 with volume ≥1.5x 30-day average or clean pullback to $130-145 zone.

Outcome

✓

Return

+0.26%

Status

scored

Overweight rating on EMR with a 4-5% portfolio position built across three tranches: 25-33% initially at $150-154, 33% on a pullback to the 10 EMA/50 SMA confluence at $148-150, and 33-42% on a test of the rising 200 SMA at $140-143 with positive MACD divergence. Stop set at $142.90 (just below rising 200 SMA), with a 25-30% trim into $160-163 strength and rebuild on confirmed close above $166 on volume >3M. Time horizon is 6-12 months through Q4 FY26 earnings (early November 2026).

Outcome

✗

Return

+1.63%

Status

scored

The three analysts converge on Underweight direction for EMR due to unconfirmed technical setup (negative MACD, lower highs), materially deteriorated leverage (net debt 2.8x, interest expense 4.4x), and goodwill vulnerability (66% of assets, negative tangible book). A 25-30% trim is calibrated based on the binding 9/16/2026 EMR decision which demonstrated that smaller trims outperform in moderating conditions with intact structural anchors and multi-week catalyst gaps. Residual position is protected with a $160-165 call sale/$140-142 put purchase collar.

Outcome

✓

Return

+1.20%

Status

scored

Maintain EMR at neutral weight (2-3% target) with stop tightened to $142.73; do not add at current ~$149.92 levels despite aggressive analyst's 2:1 R/R framing as the binding 9/16/2026 reflection showed Underweight forfeited upside when 200 SMA is intact and catalyst gap is multi-week. Add only on confirmed close above $150.77 (50 SMA) on volume >2.5M with MACD histogram turning positive, OR on scaled retest of $144-146 with the same $142.73 stop.

Outcome

✗

Return

+1.71%

Status

scored

Maintain neutral weight on EMR at Hold; the structural quality (53.2% gross margins, 3x FCF dividend coverage, rising 200 SMA at $142.63) justifies patience, but broken momentum and a 2-point stop against a 3.90 ATR create unacceptable whipsaw risk. Add only on confirmed close above $150.52 with volume >2.5M and positive MACD histogram, or on successful 200 SMA test with higher low formation; exit on weekly close below $141.50 on rising volume.

Outcome

✗

Return

+1.08%

Status

scored

The analyst recommends trimming EMR by 25-30% upfront at ~$145 levels rather than waiting for a relief rally, based on binding empirical evidence that Hold ratings at this 200 SMA approach setup historically produce -2.1% alpha loss versus SPY. A hard stop is set at $141.50 (just below the 200 SMA at $142.55), with full exit triggers including weekly close below $141.50, MACD histogram breaking below -1.5, or consensus FY27 EPS dropping below $6.50; re-engagement requires either confirmed close above $150.30 with positive MACD on volume >2.5M, or clean defense of 200 SMA with turning positive MACD histogram.

Outcome

–

Return

-0.80%

Status

scored

Analysts recommend trimming EMR exposure by 25-30% via phased execution—15% at current $147 levels with an additional 10-15% trim at the $150-153 resistance cluster—while maintaining a hard stop at $141.50 on the residual position. The Underweight rating balances the meaningful momentum breakdown (MACD bearish crossover at -0.97, RSI 41.6, price below all moving averages) against the structural 200 SMA floor at $142.47, preserving asymmetric upside into the Q4 FY26 print. Re-engagement is warranted only at the $138-142 entry zone or upon confirmed close above $153 with MACD histogram turning positive, with full exit triggered on weekly close below $141.50.

Outcome

–

Return

-0.88%

Status

scored

Trim EMR exposure by 35-40% at current $148.30 levels as the MACD histogram deteriorates (-0.91 and deepening) with a confirmed lower-high/lower-low sequence ($163.82 → $159 → $147.63 → $148.30), maintaining a hard stop at $142 (the 200 SMA structural level) while re-engagement requires two stages: first half back above $150 with MACD reversal and volume >2.5M, second half on higher-low above $142 with RSI >50 or Aspen Tech earnings validation.

Outcome

✗

Return

-2.56%

Status

scored

Maintain HOLD on EMR as all three risk analysts converged on neutral despite divergent tactical preferences, with the bull case (operating margin expansion, $3.7B TTM FCF, 1.91x net debt/EBITDA, 69-year dividend streak, intact rising 200 SMA) offset by the bear case ($7.24 forward EPS requiring ~58% expansion from $4.57 TTM that is not corroborated by print sequence, MACD bearish crossover, price below all three moving averages, RSI 42). The 200 SMA at $142.15 serves as the primary resolution mechanism: upgrade on successful defense with stabilizing EPS revisions, or downgrade on decisive breakdown on rising volume.

Outcome

✗

Return

+2.57%

Status

scored

Trim EMR from overweight toward neutral weight (~50% of target overweight), eliminating the $149 stop which is too tight at 0.82 ATR distance and will be clipped by noise. Use $147.50 as a wider technical stop or rely on the re-entry ladder as primary risk management. Re-engage with buy-limits in the $138–$142 zone around the 200 SMA, with heaviest allocation near $142, and hold reduced exposure through the Q3 FY26 print in late October/early November 2026. Do not chase into $152.86 (10 EMA) or $156.56 (Bollinger midline) without a fresh catalyst.

Outcome

–

Return

-1.19%

Status

scored

Maintain Overweight on EMR with tactical patience, targeting 110-125% of benchmark weight built gradually over 3-6 months. Existing holders should hold core positions with hard stop at $148 and trim profits above $164; new buyers should avoid initiating at current $152-155 levels and instead wait for primary entry at $145-150 or secondary zone $138-143. Key catalysts to monitor include the September FOMC decision, PPI data, and the Q4 FY26 earnings print in November.

Outcome

–

Return

-0.44%

Status

scored

Trim 40-45% of EMR exposure immediately at ~$150.21 rather than waiting for a relief rally that may not materialize, given MACD histogram steepening to -1.70, RSI at 44, and lower Bollinger band at $147.59 barely reclaimed on Sep 1. Preserve 55-60% residual for Q3 FY26 earnings optionality; re-engage only on close above $153-155 with RSI >45 and MACD histogram contracting.

Outcome

✗

Return

+1.74%

Status

scored

Maintain a Hold rating on EMR as neither aggressive nor conservative analyst conviction is strong enough to override the other. Existing holders should hold with a hard stop at $146.00, while new positions should wait for either a bullish trigger (close above $153.70 with RSI>50 and MACD bullish cross) or bearish capitulation toward the 200 SMA at $141.50.

Outcome

–

Return

+0.83%

Status

scored

Trim 25-30% of EMR position this week at $147-148 given the synchronous breakdown (50 SMA at $148.51 already breached, MACD histogram widening negative to -1.69, Bollinger lower band breached at $150.10) that mirrors the 8/28 setup where waiting cost alpha; set hard stop at $128 (below Feb-Mar 2026 swing low) and maintain 2% notional put hedge at $135 strike with 60-90 day expiry as catastrophe insurance, with contingent redeployment at $141-145 only on confirmed technical reset at Q3 print (~6-8 weeks).

Outcome

✓

Return

+0.91%

Status

scored

Maintain the 2-3% neutral-weight position with a pre-committed trigger framework that trims earlier on bearish signals ($146.97 on volume >3.5M, $144 secondary, $141 structural stop at 200 SMA) rather than waiting for the 50 SMA break that has already been violated. Add only on a pullback to $150.10 with volume >3M and MACD improvement, scaling to 3.5% with stop at $144.50. The Q4 FY26 print is the validating catalyst for re-evaluation against FY27 guidance direction, AI revenue attribution, and operating margin trajectory above 19.5%.

Outcome

✗

Return

-3.16%

Status

scored

EMR is maintained at Hold (Neutral Weight) with current ~3% position size as the high-quality franchise quality (320 bps margin expansion, 23% EPS growth, $3.71B FCF) does not justify selling, while deteriorating technicals (8 sessions of expanding negative MACD, 10 EMA resistance at $156.69, 21x forward PE requiring 59% EPS growth) do not support adding. The resolution is operational discipline with pre-committed triggers: add on close > $156.69 with volume and MACD confirmation, trim ~33% at $148.56 close on volume >2.5M with MACD confirmation, trim another ~33% at $144 close, and exit residual at $141.18 (200 SMA); a 2% notional put hedge at $140 strike (60-90 day expiry) provides tail risk insurance.

Outcome

✓

Return

-1.77%

Status

scored

Reduce EMR by ~40% in two tranches ($158-160 and $162-163) using ATR-based stops ($151 and $154.50), correcting the trader's $163 stop error, while preserving 55-60% residual for Q4 FY26 print optionality; add back 15% on sustained close above $164.30 with MACD confirmation, exit residual below $147.48, and hedge 2% of residual notional with $140 puts.

Outcome

✓

Return

-1.60%

Status

scored

Reduce EMR exposure by 33-50% via scaled tranches into the $159-164 supply zone, preserving 50-67% residual to honor the structural floor (intact FCF, dividend streak, Equinor/BP contracts) while harvesting the alpha-cost ceiling created by three consecutive Holds at this setup type producing -3.5% cumulative alpha; hard stop at $147.48 (50 SMA break) with re-engagement only on confirmed basing at $148-150 or breakout above $164.30 on volume >3M.

Outcome

✓

Return

-0.37%

Status

scored

Hold EMR at neutral weight with $144 stop and $163-167 target over 3-6 months; the structural floor has absorbed dense bearish convergence three consecutive times (8/19, 8/21, 8/24) and the 8/25 meta-lesson requires fresh evidence before deviating from Hold, not pattern-matching to the same checklist that produced negative alpha in prior applications.

Outcome

✗

Return

+2.15%

Status

scored

Downgrade from Hold to Underweight with a 25-30% position trim executed at current levels ($154-157), maintaining 70-75% residual exposure; stop loss set at $148.05 (50 SMA defense). The rating is supported by dense bearish convergence—confirmed MACD bearish crossover with deepening histogram, price below both 10 EMA and VWMA, and RSI cooling from overbought—combined with elevated 21.4x forward multiple, making the 8/24 EMR lesson on overriding passive-hold reflex applicable. Re-engagement triggers only on confirmed basing (MACD histogram contraction + 10 EMA reclaim on volume, or positive RSI divergence in $148-150) following Q4 FY26 print validation.

Outcome

✓

Return

-1.66%

Status

scored

Emerson Electric maintains a Hold rating at neutral weight, rejecting both the aggressive analyst's Buy recommendation and the neutral analyst's modest trim suggestion, citing an identical setup to the 8/21 reflection where the structural floor absorbed bearish inventory at comparable prices. The key correction to the trader's proposal is tightening the stop loss to $144.00 (below the 50 SMA at $147.80) rather than setting it equal to entry, which provides actual downside protection. A 2% put hedge at $140 strike serves as catastrophe insurance against the sector-contagion scenario.

Outcome

✓

Return

+0.20%

Status

scored

Maintain EMR at neutral weight (Hold) despite bearish analyst convergence, as the 8/20 reflection demonstrates that a comparable setup at $154-157 with identical risk inventory produced +1.6% raw and +1.2% alpha when EMR rallied. The disciplined posture converts the passive Hold failure mode into executable discipline via a pre-committed trim trigger at $147.48 on volume confirmation, avoiding the trim-tax that proactive action extracted in prior instances.

Outcome

✗

Return

+1.64%

Status

scored

Execute a ~25-30% preemptive trim at $154.72 given a dense risk cluster (1.46:1 R/R, negative MACD histogram, 5 successive lower closes, FY27 EPS execution requirements, and balance sheet fragility including net debt rising from $4.1B to $11.57B in two years), while maintaining 70-75% residual exposure to preserve participation in the structural bull thesis anchored by Q3's 19.8% operating margin beat, the 67-year dividend streak, and a compelling AI/automation catalyst pipeline including DeltaV for Data Centers and Ovation AI.

Outcome

✓

Return

-1.83%

Status

scored

Portfolio Manager maintains HOLD on EMR at $157.60 with neutral weight and no sizing caveat — rejecting both aggressive adds and defensive trims absent pre-committed trigger conditions. Stop loss is tightened to $150.00 (from $146.81), price target anchored at $163-167, with five conditional triggers covering preemptive trim at $154.72, pullback add zone at $146-$150, breakout add at $164, trim-into-strength protocol, and a 2% notional put hedge at $145 strike for 60-90 days. Time horizon is 3-6 months into Q4 FY26 earnings print.

Outcome

✓

Return

-0.11%

Status

scored

Portfolio managers converge on Hold for EMR at $157.78, citing symmetric bull/bear risk around the current entry point—the bull case ($170) requires both perfect execution AND multiple expansion while the bear case ($140-145) needs only one adverse catalyst. The framework tightens stop loss to $150 (from $146) with pre-committed 25% trim triggers at $154.72 on volume >2.5M or hawkish FOMC, a $146-$150 add zone with reversal confirmation, and a 2% put hedge at $145 strike for catastrophe protection, targeting $163-167 over a 3-6 month horizon into Q4 FY26 earnings.

Outcome

✗

Return

-2.63%

Status

scored

Maintain EMR at benchmark weight or slightly below; the Q3 earnings print (710 bps gross margin expansion, FY26 EPS $6.55, $3.7B FCF) and AI/automation productization support the core thesis, but 35.46x TTM P/E at 97% of the 52-week high with hostile macro (30Y at 19-year highs, 48% Fed hike probability) and deteriorating volume (down 68% from breakout) justify waiting for a pullback. Add on a 3-4% pullback to the $155-158 VWMA zone ($156.69) rather than chasing near the aggressive $159-160 level or waiting for the damaging $146-148 breakdown level.

Outcome

✓

Return

-0.69%

Status

scored

Maintain EMR at $163.17 without adding or trimming, as the reward-to-risk of ~2.2-to-1 against makes chasing into the upper Bollinger Band (~$170.75) costly. The hard stop sits at $158.59 (one ATR below the breakout level), with incremental adds reserved for pullbacks to the 10-day EMA (~$159.76) or 50-day SMA (~$146.11) with RSI reset confirmation. A full reassessment will occur at the Q4 FY26 print in early November 2026.

Outcome

✓

Return

-0.63%

Status

scored

Analysts unanimously recommend HOLD on EMR at ~$164, citing 12.7% extension above the 50 SMA and bearish RSI divergence as risks despite 21% three-week gains, while acknowledging $3.7B TTM FCF, $2.4B annual capital return, and DeltaV AI exposure as structural supports. Execute a simplified framework: maintain core position, set trailing stop at $154, stage incremental adds only at the $145-150 zone, and wait for Q4 FY26 print (early November) to validate FY27 trajectory before scaling exposure.

Outcome

–

Return

+0.25%

Status

scored

Reduce EMR exposure by 30-35% at current $163-165 zone, moving to approximately 70% of benchmark weight, with a hard stop on the remaining position at $152.88 (breakout level/structural invalidation); do not place buy-stops above current price or pre-commit to specific re-entry zones. Re-evaluate based on Q4 FY26 earnings print (early November 2026) and any pullback toward the 50 SMA ($145.22), while avoiding shorting since the trend remains structurally intact.

Outcome

✓

Return

-0.35%

Status

scored

Maintain HOLD rating on EMR as the existing core position represents the trade rather than a placeholder for re-entry. Risk/reward from current levels is roughly symmetric (15-20% upside to $190-200 vs. 12-15% downside to $140-145), and the 22.73x forward P/E with 89% goodwill-to-equity does not justify adding at the overbought $164 entry. Add 25% only on a pullback to the $154-158 zone (10 EMA), with up to 30-35% position increase if the deeper $147-150 zone materializes.

Outcome

✗

Return

+3.57%

Status

scored

Analysts converge on HOLD for EMR, recognizing strong Q3 fundamentals (+23% EPS, record $1.32B FCF, 750bps gross margin expansion) but viewing the recent +11% rally as having captured near-term re-rating. The blended 22–24x multiple is supported by data, not the 26–27x aggressive case; the $145 hard stop (widened from $148) accommodates the $4.79 ATR. New capital should wait for tiered entry at $155–157 (25%) and $147–150 (25–35%), with re-rating triggers at >$165 (upgrade) and <$140 (downgrade).

Outcome

✓

Return

+0.28%

Status

scored

Maintain the current EMR position with disciplined tiered execution rather than chasing at $158, where the unresolved $0.68 Street-vs-guidance EPS gap and failed $164.85 Bollinger rejection present insufficient risk-reward. Add 25% of position on pullback to $144-150 (50 SMA zone) with flexibility to increase to 30-35% if support holds with expanding volume on the bounce, and stop at $140.50.